| ADI | Acceptable Daily Intake |
| ADME | Absorption, Distribution, Metabolism, Excretion |
| AMKL | Acute Megakaryoblastic Leukaemia |
| ARfD | Acute Reference Dose |
| BMD | Benchmark Dose |
| BMDL | Lower confidence Limit of the Benchmark Dose |
| BMR | Benchmark Response |
| CDKs | Cyclin‐dependent kinases |
| cGAMP or cyclic GMP–AMP | Cyclic guanosine monophosphate–adenosine monophosphate |
| cGAS | Cyclic guanosine monophosphate–adenosine monophosphate synthase |
| CREST | Calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly and telangiectasia |
| CSGMT | Collaborative Study Group of the Micronucleus Test |
| CytB | Cytochalasin B |
| FISH | Fluorescence in situ hybridisation |
| GIT | Gastrointestinal Tract |
| GIT MN assay | Gastrointestinal Tract Micronucleus assay |
| HBGV | Health‐Based Guidance Value |
| IWGT | International Workshop on Genotoxicity Test |
| IWGTP | International Workshop on Genotoxicity Test Procedures |
| JEMS | Japanese Environmental Mutagen Society |
| MMS | Mammalian Mutagenicity Study |
| MN | Micronucleus/micronuclei |
| MOE | Margin of Exposure |
| NOAEL | No Observed Adverse Effect Level |
| NOEL | No Observed Effect Level |
| OECD | Organisation for Economic Co‐operation and Development |
| OECD TG 471 | Bacteria reverse mutation text guideline (AMES test) |
| OECD TG 474 | The mammalian erythrocyte micronucleus test guideline |
| OECD TG 487 | In vitro mammalian cell micronucleus test guideline |
| OECD TG 488 | Transgenic rodent assay |
| OECD TG 489 | In vivo mammalian alkaline comet assay |
| SC | Scientific Committee |
| TDI | Tolerable Daily Intake |
| ToR | Terms of Reference |
| TTC | Threshold of Toxicological Concern |
| UF | Uncertainty Factor |
| WHO | World Health Organization |